Tesamorelin 5mg

Tesamorelin 

Description:

Tesamorelin, a synthetic analogue of Growth Hormone Releasing Hormone (GHRH), is primarily utilized to decrease excess abdominal fat in HIV-associated lipodystrophy patients. This metabolic disorder, characterized by insulin resistance, fat redistribution, and hyperlipidemia, often develops due to antiretroviral therapy for HIV. Produced by Theratechnologies, a Canadian company, Tesamorelin was sanctioned by the FDA in 2010 for clinical applications.

Clinical Applications:

 • HIV-Associated Lipodystrophy: Tesamorelin effectively reduces abdominal fat accumulation caused by specific HIV treatments.

 • Fat Reduction: It targets and diminishes abdominal fat.

 • Peripheral Nerve Health: Research is being conducted to assess its potential in enhancing peripheral nerve regeneration.

 • Cognitive Function: It is under investigation for its capability to decelerate the progression of mild cognitive impairment (MCI), a precursor to dementia.

Mechanism of Action:

Tesamorelin is a stabilized version of GHRH with an added trans-3-hexanoic acid group. It promotes growth hormone release, leading to a decrease in abdominal fat and improved metabolic profiles in patients.

Research and Development:

Tesamorelin continues to be studied for additional benefits beyond its primary use, including cognitive enhancement and regenerative effects. Its safety and effectiveness are being assessed through ongoing clinical trials.

Usage:

 • Indications: Primarily prescribed for reducing abdominal fat in HIV-infected patients with lipodystrophy.

What is Tesamorelin?

Tesamorelin is a synthetic form of human growth hormone-releasing hormone (GHRH). It stimulates the production and release of growth hormone (GH) in the body. Developed by Theratechnologies Inc. to treat lipodystrophy in HIV patients, it received FDA approval in 2010 under the brand name Egrifta.

What Does Tesamorelin Do?

Tesamorelin, consisting of 44 amino acids and a trans-3-hexenoic acid group, acts similarly to GHRH but is more stable. It binds to GHRH receptors in the anterior pituitary gland, triggering the release of GH. GH plays a vital role in tissue building and repair, influencing muscle growth, tissue repair, and fat metabolism. Tesamorelin addresses issues like growth hormone deficiency, fat accumulation, cognitive decline, and nerve injury.

Benefits and Clinical Trials:

 • Reduction of Adipose Tissue: Tesamorelin is approved to reduce abdominal fat in HIV patients with lipodystrophy. It has demonstrated a 15% reduction in subcutaneous fat while improving insulin resistance and cholesterol levels. Patients also report enhanced body image.

 • Recovery from Peripheral Nerve Damage: Emerging research supports that tesamorelin may boost nerve regeneration, potentially aiding those with peripheral nerve injuries.

 • Improved Cognitive Function: Preliminary studies suggest that tesamorelin may elevate neurotransmitter levels associated with cognitive health, though more research is necessary.

Conclusion:

Tesamorelin has proven effective in reducing body fat and improving various health metrics, with continued research exploring its broader therapeutic potential.

Common Side Effects:

Swelling and itching at the injection site

Muscle aches and pain

Diarrhea

Sweating

Less Common but Serious Side Effects:

Diarrhea accompanied by fever and dehydration

Shortness of breath

Muscle or joint pain

Numbness, tingling, or swelling in the arms or legs

Risks:

Glucose intolerance and increased risk of type 2 diabetes mellitus

Contraindicated during pregnancy

Is Tesamorelin Safe?

The FDA has approved injectable tesamorelin for treating HIV-associated lipodystrophy, based on safety and efficacy demonstrated in Phase 3 clinical trials. For this specific use, tesamorelin is deemed safe and effective.

For non-prescription uses, including general weight loss, the risks and benefits should be carefully considered. Non-prescription tesamorelin should only be handled by qualified professionals and not self-administered for non-research purposes.

Dosage Information

For Research Purposes: Commonly 1 mg per dose, injected subcutaneously late at night, with dosing adjusted as needed. Research applications often use cyclical dosing, varying in length.

Product Use: THIS PRODUCT IS STRICTLY FOR SCIENTIFIC RESEARCH PURPOSES ONLY. It should only be used in laboratory settings. All product information on this website is provided solely for educational purposes. The law strictly prohibits introducing this product into the body of humans or animals. Only licensed professionals should handle this product. This product is not a drug, food, or cosmetic and should not be improperly classified or used as such.